ClinConnect ClinConnect Logo
Search / Trial NCT06070961

Prospective Biological Study to Evaluate the Persistence of COVID-19 Vaccine and Other Vaccines'-Induced Immune Responses in Follicular Lymphoma Patients Undergoing Frontline Induction Immuno-chemotherapy and Anti-CD20 Maintenance

Launched by FONDAZIONE ITALIANA LINFOMI - ETS · Oct 3, 2023

Trial Information

Current as of July 22, 2025

Recruiting

Keywords

Lymphoma Follicular Immunochemotherapy Fl Vaccine Covid19 Sars Cov 2 Tetanus Zoster Vzv Rituximab Obinotuzumab Foll19 Fil Foll19 Diphtheria Maintenance Humoral Cellular Immunity Induction

ClinConnect Summary

This clinical trial is studying how long the immune response from COVID-19 vaccines and other vaccines (like those for shingles, diphtheria, and tetanus) lasts in patients with Follicular Lymphoma who are receiving specific treatments. Researchers will collect blood samples from participants at different times during their treatment to check how well their bodies are responding to these vaccines. This will help us understand the effectiveness of vaccination in people undergoing cancer treatment.

To be eligible for this study, participants need to be part of another ongoing study (called FIL_FOLL19), have received at least three doses of a COVID-19 vaccine, and have records of their vaccinations. There are no specific exclusions, so many patients may qualify. If you join the study, you can expect to provide blood samples at planned times to help the researchers gather important information about your immune response. Your involvement will contribute to valuable insights into how vaccines work for patients undergoing treatment for Follicular Lymphoma.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Enrolment in FIL_FOLL19 study
  • 2. Previous vaccination for COVID-19 (at least 3 doses)
  • 3. Availability of informations about COVID-19 and other vaccines previously administered (vaccination records)
  • 4. Willingness to comply with blood collection timepoints required for vaccination immunity evaluation
  • 5. Signature of specific informed consent form
  • Exclusion Criteria:
  • None

About Fondazione Italiana Linfomi Ets

Fondazione Italiana Linfomi - ETS is a leading research organization dedicated to advancing the understanding and treatment of lymphoid malignancies. With a focus on promoting clinical trials and innovative therapeutic approaches, the foundation collaborates with healthcare professionals, academic institutions, and pharmaceutical companies to enhance patient care and outcomes. Its mission encompasses fostering research initiatives, facilitating education, and supporting the development of new strategies to combat lymphomas, ultimately aiming to improve the quality of life for patients affected by these diseases.

Locations

Firenze, , Italy

Reggio Emilia, , Italy

Alessandria, It, Italy

Biella, It, Italy

Milano, It, Italy

Milano, It, Italy

Novara, It, Italy

Pavia, It, Italy

Piacenza, It, Italy

Torino, It, Italy

Torino, It, Italy

Varese, It, Italy

Siena, , Italy

Brescia, , Italy

Avellino, Av, Italy

Patients applied

0 patients applied

Trial Officials

Michele Merli, MD

Principal Investigator

U.O.C Ematologia, Ospedale di Circolo, Varese

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported